NEW YORK (GenomeWeb) – The Structural Genomics Consortium and the CHDI Foundation have struck an agreement to discover and characterize new drug targets for Huntington's disease and to make their findings available for use by academic researchers and pharmaceutical and biotechnology companies.

Neither the SGC nor CHDI will file for patents on any of their research findings, but will make all the reagents and knowledge they generate widely available without restrictions, the partners said yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.